
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Here is a quick look at some of the drugs most recently FDA-approved for primary care diseases.
The FDA approved a host of new drugs in 2015. Here is a very brief look at some the most recently approved.Sourceshttp://www.centerwatch.com/drug-information/fda-approved-drugs/http://www.drugs.com/newdrugs.html






